{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:23:13Z","timestamp":1794288193801,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Drug resistance is a major obstacle to the long-term effectiveness of cancer therapies. Approximately 70% of breast cancer patients relapse after 5 years of treatment, and the lack of biomarkers associated with drug resistance translates to poor prognosis in the clinic. Previous research has utilised omics approaches to uncover biomarkers driving drug resistance, with a strong emphasis on genetic mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we identified a nine-marker signature associated with resistance to lapatinib in a HER2-positive breast cancer model using a target discovery approach by employing an integrative multi-omics strategy, combining ATAC-seq, RNA-seq and proteomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that seven markers in the drug resistance-signature had not been previously found to be implicated in HER2-positive breast cancer, some of which we further validated using an additional lung cancer model. We counterintuitively found that drug-resistant cells have restrictive chromatin accessibility with reduced gene expression associated with limited total proteome changes. However, upon closer look, we identified that the drug resistance-signature had increased chromatin accessibility near the transcriptional start sites of those seven markers and was highly differentially expressed across the three datasets. Our data show that despite the overall transcriptional and proteomic landscape showing limited changes, there are several markers that are highly expressed, which correlate with increased anchorage-independent and invasive phenotype in vitro in lapatinib-resistant cells compared to cancer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results demonstrate that disease aggressiveness can be related to reduced chromatin and gene expression dynamics. We anticipate that the resistant signature identified here using an integrative target discovery approach can be applied to complex, more representative models and validated before they can be targeted by suitable therapeutic agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03174-3","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T06:03:31Z","timestamp":1757743411000},"page":"1471-1482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer"],"prefix":"10.1038","volume":"133","author":[{"given":"J.","family":"Steggall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-4291","authenticated-orcid":false,"given":"V.","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Al-Subaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0277-7668","authenticated-orcid":false,"given":"A.","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"3174_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.csbj.2021.12.028","volume":"20","author":"J Yang","year":"2021","unstructured":"Yang J, Ju J, Guo L, Ji B, Shi S, Yang Z, et al. Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning. Comput Struct Biotechnol J. 2021;20:333\u201342.","journal-title":"Comput Struct Biotechnol J"},{"key":"3174_CR2","first-page":"13","volume":"2","author":"C Oakman","year":"2010","unstructured":"Oakman C, Pestrin M, Zafarana E, Cantisani E, Di Leo A. Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer Manag Res. 2010;2:13\u201325.","journal-title":"Cancer Manag Res"},{"key":"3174_CR3","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1002\/cam4.963","volume":"5","author":"Y Xin","year":"2016","unstructured":"Xin Y, Guo WW, Huang Q, Zhang P, Zhang L, Jiang G, et al. Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2\u2010positive breast cancer: a meta\u2010analysis of randomized controlled trials. Cancer Med. 2016;5:3454.","journal-title":"Cancer Med"},{"key":"3174_CR4","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Kakkar R. Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer. 2012;4:35\u201351.","DOI":"10.2147\/BCTT.S29996"},{"key":"3174_CR5","doi-asserted-by":"crossref","unstructured":"Wahdan-Alaswad R, Liu B, Thor AD. Targeted lapatinib anti-HER2\/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. Cancer Drug Resist. 2020;3:179\u201398.","DOI":"10.20517\/cdr.2019.92"},{"key":"3174_CR6","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.celrep.2018.02.028","volume":"22","author":"AE Fearon","year":"2018","unstructured":"Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker A, Kapitonova E, et al. PHLDA1 mediates drug resistance in receptor tyrosine kinase-driven cancer. Cell Rep. 2018;22:2469\u201381.","journal-title":"Cell Rep"},{"key":"3174_CR7","doi-asserted-by":"crossref","unstructured":"Jian W, Zhang X, Wang J, Liu Y, Hu C, Wang X, et al. Scinderin-knockdown inhibits proliferation and promotes apoptosis in human breast carcinoma cells. Oncol Lett. 2018;16:3207\u201314.","DOI":"10.3892\/ol.2018.9009"},{"key":"3174_CR8","doi-asserted-by":"crossref","unstructured":"Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12:1786.","DOI":"10.1038\/s41467-021-22024-3"},{"key":"3174_CR9","doi-asserted-by":"crossref","unstructured":"Wang Y, Li Z, Bai L, Zhang D, Zhang T, Ren F. Scinderin is a novel oncogene for its correlates with poor prognosis, immune infiltrates and matrix metalloproteinase-2\/9 (MMP2\/9) in glioma. Brain Sci. 2022;12:1415.","DOI":"10.3390\/brainsci12101415"},{"key":"3174_CR10","doi-asserted-by":"crossref","unstructured":"Schratter G, Scheruebel S, Langthaler S, Ester K, Pelzmann B, Ghaffari-Tabrizi-Wizsy N, et al. GIRK1 triggers multiple cancer-related pathways in the benign mammary epithelial cell line MCF10A. Sci Rep. 2019;9:19277.","DOI":"10.1038\/s41598-019-55683-w"},{"key":"3174_CR11","doi-asserted-by":"crossref","unstructured":"Sehgal P, Chaturvedi P. Chromatin and cancer: implications of disrupted chromatin organization in tumorigenesis and its diversification. Cancers. 2023;15:466.","DOI":"10.3390\/cancers15020466"},{"key":"3174_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201800113","volume":"13","author":"S Doll","year":"2019","unstructured":"Doll S, Gnad F, Mann M. The case for proteomics and phospho-proteomics in personalized cancer medicine. Proteom Clin Appl. 2019;13:e1800113.","journal-title":"Proteom Clin Appl"},{"key":"3174_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-0716-2513-2_14","volume":"2535","author":"F de Nicola","year":"2022","unstructured":"de Nicola F, Corleone G, Goeman F. Dissecting the epigenome driving drug resistance by ATAC-seq. Methods Mol Biol. 2022;2535:171\u201385.","journal-title":"Methods Mol Biol"},{"key":"3174_CR14","doi-asserted-by":"crossref","unstructured":"Lin Q, Li J, Zhu D, Niu Z, Pan X, Xu P, et al. Aberrant scinderin expression correlates with liver metastasis and poor prognosis in colorectal cancer. Front Pharmacol. 2019;10:1183.","DOI":"10.3389\/fphar.2019.01183"},{"key":"3174_CR15","doi-asserted-by":"crossref","unstructured":"Li W, Huang L, Qi N, Zhang Q, Qin Z. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target. BMC Genom. 2024;25:183.","DOI":"10.1186\/s12864-024-10056-0"},{"key":"3174_CR16","doi-asserted-by":"crossref","unstructured":"Balcioglu O, Gates BL, Freeman DW, Hagos BM, Mehrabad EM, Ayala-Talavera D, et al. Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src\/Akt\/Stat3 attenuation. NPJ Breast Cancer. 2024;10:80.","DOI":"10.1038\/s41523-024-00687-7"},{"key":"3174_CR17","doi-asserted-by":"crossref","unstructured":"Gorbacheva AM, Uvarova AN, Ustiugova AS, Bhattacharyya A, Korneev KV, Kuprash DV, et al. EGR1 and RXRA transcription factors link TGF-\u03b2 pathway and CCL2 expression in triple negative breast cancer cells. Sci Rep. 2021;11:14120.","DOI":"10.1038\/s41598-021-93561-6"},{"key":"3174_CR18","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049894","volume":"16","author":"A Hayat","year":"2023","unstructured":"Hayat A, Carter EP, King HW, Ors A, Doe A, Teijeiro SA, et al. Low HER2 expression in normal breast epithelium enables dedifferentiation and malignant transformation via chromatin opening. Dis Model Mech. 2023;16:dmm049894 https:\/\/doi.org\/10.1242\/dmm.049894.","journal-title":"Dis Model Mech"},{"key":"3174_CR19","doi-asserted-by":"crossref","unstructured":"Hanna A, Nixon MJ, Estrada MV, Sanchez V, Sheng Q, Opalenik SR, et al. Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer. Breast Cancer Res. 2022;24:51.","DOI":"10.1186\/s13058-022-01542-y"},{"key":"3174_CR20","doi-asserted-by":"crossref","unstructured":"Yang Y, Zhang J, Yan Y, Cai H, Li M, Sun K, et al. Low expression of Rap1GAP is associated with epithelialmesenchymal transition (EMT) and poor prognosis in gastric cancer. Oncotarget. 2016;8:8057\u201368.","DOI":"10.18632\/oncotarget.14074"},{"key":"3174_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","volume":"38","author":"JD Hayes","year":"2020","unstructured":"Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38:167.","journal-title":"Cancer Cell"},{"key":"3174_CR22","doi-asserted-by":"crossref","unstructured":"Rashid NS, Boyd DC, Olex AL, Grible JM, Duong AK, Alzubi MA, et al. Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer. Sci Rep. 2022;12:21248.","DOI":"10.1038\/s41598-022-25541-3"},{"key":"3174_CR23","doi-asserted-by":"crossref","unstructured":"Sheng N, Yan L, Wu K, You W, Gong J, Hu L, et al. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis. 2018;9:402.","DOI":"10.1038\/s41419-018-0434-z"},{"key":"3174_CR24","doi-asserted-by":"crossref","unstructured":"Zhang X, Shi L, Sun H, Wang Z, Xu F, Wei J, et al. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple\u2010negative breast cancer progression via an m6A\u2010dependent manner. Clin Transl Med. 2023;13:e1427.","DOI":"10.1002\/ctm2.1427"},{"key":"3174_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.21037\/gs-23-127","volume":"12","author":"L Jiang","year":"2023","unstructured":"Jiang L, Liu Y, Pan Y, Tan Z, Wang J, Zheng G, et al. Silencing of AJAP1 expression by promoter methylation activates the Wnt\/\u03b2-catenin signaling pathway to promote tumor proliferation and metastasis in salivary adenoid cystic carcinoma. Gland Surg. 2023;12:834.","journal-title":"Gland Surg"},{"key":"3174_CR26","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.21873\/anticanres.12961","volume":"38","author":"K Kuhara","year":"2018","unstructured":"Kuhara K, Tokuda K, Kitagawa T, Baron B, Tokunaga M, Harada K, et al. CUB domain-containing protein 1 (CDCP1) is down-regulated by active hexose-correlated compound in human pancreatic cancer cells. Anticancer Res. 2018;38:6107.","journal-title":"Anticancer Res"},{"key":"3174_CR27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/carcin\/bgs167","volume":"33","author":"Y Park","year":"2012","unstructured":"Park Y, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee S, et al. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012;33:1843.","journal-title":"Carcinogenesis"},{"key":"3174_CR28","unstructured":"Barkardottir RB, Johannsdottir HK, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, et al. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables. Anticancer Res. 2004;24:2681\u20137."},{"key":"3174_CR29","doi-asserted-by":"crossref","unstructured":"Panigrahi A, O\u2019malley BW. Mechanisms of enhancer action: the known and the unknown. Genome Biol. 2021;22:108.","DOI":"10.1186\/s13059-021-02322-1"},{"key":"3174_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3892\/ijo.2016.3749","volume":"50","author":"W Yang","year":"2016","unstructured":"Yang W, Wang X, Zheng W, Li K, Liu H, Sun Y. Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma. Int J Oncol. 2016;50:340.","journal-title":"Int J Oncol"},{"key":"3174_CR31","doi-asserted-by":"crossref","unstructured":"Mendon\u00e7a V, Soares-Lima SC, Moreira MAM. Exploring cross-tissue DNA methylation patterns: blood\u2013brain CpGs as potential neurodegenerative disease biomarkers. Commun Biol. 2024;7:904.","DOI":"10.1038\/s42003-024-06591-x"},{"key":"3174_CR32","doi-asserted-by":"crossref","unstructured":"Paris J, Wilhelm C, Lebb\u00e9 C, Elmallah M, Pamoukdjian F, H\u00e9raud A, et al. PROM2 overexpression induces metastatic potential through epithelial\u2010to\u2010mesenchymal transition and ferroptosis resistance in human cancers. Clin Transl Med. 2024;14:e1632.","DOI":"10.1002\/ctm2.1632"},{"key":"3174_CR33","unstructured":"Zhang W, Zhou Q, Wei Y, Da M, Zhang C, Zhong J, et al. The exosome-mediated PI3k\/Akt\/mTOR signaling pathway in cervical cancer. Int J Clin Exp Pathol. 2019;12:2474\u201384."},{"key":"3174_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101051","volume":"14","author":"R Suresh","year":"2021","unstructured":"Suresh R, Diaz RJ. The remodelling of actin composition as a hallmark of cancer. Transl Oncol. 2021;14:101051.","journal-title":"Transl Oncol"},{"key":"3174_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188789","volume":"1877","author":"X Li","year":"2022","unstructured":"Li X, Zhao L, Chen C, Nie J, Jiao B. Can EGFR be a therapeutic target in breast cancer? Biochim Biophys Acta Rev Cancer. 2022;1877:188789.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3174_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13148-021-01105-6","volume":"13","author":"J Gallon","year":"2021","unstructured":"Gallon J, Loomis E, Curry E, Martin N, Brody L, Garner I, et al. Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance. Clin Epigenetics. 2021;13:122\u20136.","journal-title":"Clin Epigenetics"},{"key":"3174_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145808","volume":"799","author":"R Murad","year":"2021","unstructured":"Murad R, Avanes A, Ma X, Geng S, Mortazavi A, Momand J. Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells. Gene. 2021;799:145808.","journal-title":"Gene"},{"key":"3174_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113191","volume":"42","author":"Y Audet-Delage","year":"2023","unstructured":"Audet-Delage Y, St-Louis C, Minarrieta L, McGuirk S, Kurreal I, Annis MG, et al. Spatiotemporal modeling of chemoresistance evolution in breast tumors uncovers dependencies on SLC38A7 and SLC46A1. Cell Rep. 2023;42:113191.","journal-title":"Cell Rep"},{"key":"3174_CR39","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1111\/cas.15798","volume":"114","author":"L Hua","year":"2023","unstructured":"Hua L, Song Y, Min J, Wang R, Li H, Zhu L, et al. AKR7A3 modulates the metastasis of pancreatic ductal adenocarcinoma through regulating PHGDH-suppressed autophagy. Cancer Sci. 2023;114:3101\u201313.","journal-title":"Cancer Sci"},{"key":"3174_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1101\/gad.253591.114","volume":"29","author":"L Wang","year":"2015","unstructured":"Wang L, Yang H, Abel EV, Ney GM, Palmbos PL, Bednar F, et al. ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis. Genes Dev. 2015;29:171\u201383.","journal-title":"Genes Dev"},{"key":"3174_CR41","doi-asserted-by":"publisher","first-page":"a007906","DOI":"10.1101\/cshperspect.a007906","volume":"4","author":"KM Cadigan","year":"2012","unstructured":"Cadigan KM, Waterman ML. TCF\/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol. 2012;4:a007906 https:\/\/doi.org\/10.1101\/cshperspect.a007906","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3174_CR42","doi-asserted-by":"crossref","unstructured":"Iwafuchi-Doi M. The mechanistic basis for chromatin regulation by pioneer transcription factors. Wiley Interdiscip Rev Syst Biol Med. 2018;11:e1427.","DOI":"10.1002\/wsbm.1427"},{"key":"3174_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2021.07.015","volume":"518","author":"BJ Petri","year":"2021","unstructured":"Petri BJ, Piell KM, South Whitt GC, Wilt AE, Poulton CC, Lehman NL, et al. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells. Cancer Lett. 2021;518:152\u201368.","journal-title":"Cancer Lett"},{"key":"3174_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.937831","volume":"12","author":"KK Reddi","year":"2022","unstructured":"Reddi KK, Guruvaiah P, Edwards YJK, Gupta R. Changes in the transcriptome and chromatin landscape in BRAFi-resistant melanoma cells. Front Oncol. 2022;12:937831.","journal-title":"Front Oncol"},{"key":"3174_CR45","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1073\/pnas.1821889116","volume":"116","author":"R Gupta","year":"2019","unstructured":"Gupta R, Bugide S, Wang B, Green MR, Johnson DB, Wajapeyee N. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Proc Natl Acad Sci USA. 2019;116:4583\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3174_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","volume":"35","author":"JL Hsu","year":"2017","unstructured":"Hsu JL, Hung M. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2017;35:575.","journal-title":"Cancer Metastasis Rev"},{"key":"3174_CR47","doi-asserted-by":"crossref","unstructured":"Kumar N, Cramer GM, Dahaj SAZ, Sundaram B, Celli JP, Kulkarni RV. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. Sci Rep. 2019;9:10845.","DOI":"10.1038\/s41598-019-46926-x"},{"key":"3174_CR48","doi-asserted-by":"publisher","first-page":"995","DOI":"10.20517\/cdr.2022.63","volume":"5","author":"D Furrer","year":"2022","unstructured":"Furrer D, Dragic D, Chang S, Fournier F, Droit A, Jacob S, et al. Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic review. Cancer Drug Resist. 2022;5:995.","journal-title":"Cancer Drug Resist"},{"key":"3174_CR49","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2009","unstructured":"Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2009;10:515.","journal-title":"Cancer Cell"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03174-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03174-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:16:49Z","timestamp":1762885009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03174-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,11,30]]}},"alternative-id":["3174"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03174-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.08.621581","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not require ethics approval as it did not involve human participants, animal subjects or other sensitive data, and no personal or identifiable information was collected or used. As such, ethics committee review and approval were not necessary in accordance with the institutional regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}